Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31201 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Amanda Lipsitt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Pneumocystis carinii, Pneumonia, Pneumocystis. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Lebanese Syrian Associated Charities, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Pneumocystis jirovecii pneumonia (PJP) in hematopoietic cell transplant (HCT) recipients can be prevented by efficient prophylaxis. We surveyed HCT centers in North America to assess their PJP prophylaxis practices. Most institutions used intravenous (IV) pentamidine (29.6%) or inhaled pentamidine (14.8%); 37% institutions changed from trimethoprim/sulfamethoxazole (TMP‐SMX) to another medication after conditioning; and 44% administered no PJP prophylaxis during the pre‐engraftment period. Most institutions avoided using TMP‐SMX during the pre‐engraftment period, mainly because of concerns about myelotoxicity, despite this being the preferred PJP prophylaxis agent. There is a need to evaluate the effects of TMP‐SMX on engraftment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Akshay Sharma
Förderung
- American Lebanese Syrian Associated Charities
- NCI NIH HHS
- NHLBI NIH HHS
- National Institutes of Health (NIH)/National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute
Zitieren
APA
Lipsitt, A., Hijano, D. R., Ferrolino, J. A., Dallas, R., Sharma, A., & Maron, G. (2024). Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31201
Vancouver
Lipsitt A, Hijano DR, Ferrolino JA, Dallas R, Sharma A, Maron G. Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31201
BibTeX
@article{Lipsitt2024,
author = {Lipsitt, Amanda and Hijano, Diego R and Ferrolino, Jose A and Dallas, Ronald and Sharma, Akshay and Maron, Gabriela},
title = {Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31201}
}
EUVIMED